Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 1 clinical study titled ‘A Phase 1, ...

Most important is anti-blood-clot medicine Eliquis, which is due to lose patent exclusivity in 2026. Eliquis emerged last year as Pfizer’s top-performing drug, having grown rapidly to bring in $7.4bn ...

Can Boston stay on top in biotech? Find out on Sept 17, 6-9 p.m. EDT to explore talent shifts, funding, and Boston’s future.

Schrödinger is discontinuing the development of its blood cancer CDC7 inhibitor after two patient deaths. In a Phase I trial ...

Health Secretary Robert F. Kennedy Jr.’s Make America Healthy Again campaign to combat chronic disease is reshaping state ...

Zydus Lifesciences: The drug maker has received a clean outcome from the US FDA after a pre-approval inspection (PAI) at its ...

The expedited approval of mpox vaccines is critical to addressing this public health emergency. Building on the practice in approving COVID-19 vaccines, this analysis investigates the regulatory ...

Patients with MASH and stage II or III fibrosis treated with ervogastat and clesacostat are more likely than those on placebo ...

Europe, Ukraine hope for chilly Putin summit ▪ The Hill interview: Newsom defends redistricting fight ▪ Progressives take center stage in mayoral contests ▪ Israel steps up ...

Legend Biotech announced its Q2 earnings, reporting $439m of revenues for its only commercial product, the cell therapy ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.